Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04803-0
Abstract: Dear Editor, We have read with great interest the report by Wang et al. [1] regarding autologous hematopoietic stem cell transplantation (ASCT) following polatuzumab vedotin combined with rituximab-bendamustine (Pola-BR) for relapsed diffuse large B-cell lymphoma… read more here.
Keywords: bendamustine; therapy; pola; cell ... See more keywords
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18341
Abstract: Polatuzumab vedotin (Pola) is an antibody–drug conjugate that targets the B‐cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B‐cell lymphoma… read more here.
Keywords: rationale combination; combination; rit; pola ... See more keywords
Revealing the Synergistic Potential of Mosunetuzumab Plus Polatuzumab Vedotin through CD20 Upregulation
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198107
Abstract: Background Despite the development of effective therapies for aggressive non-Hodgkin lymphoma, such as polatuzumab vedotin (Pola) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), approximately 20-40% of patients experience relapsed or refractory disease after… read more here.
Keywords: cd20; plus pola; combination; mosun plus ... See more keywords
Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200395
Abstract: Background: Epcor, a subcutaneous CD3xCD20 bispecific antibody, is approved as monotherapy for adults with relapsed or refractory DLBCL after ≥2 lines of systemic therapy. Combining epcor with antineoplastic agents that have complementary mechanisms of action… read more here.
Keywords: treatment; pola; mrd negativity; epcor ... See more keywords
CD5 positivity and aberrant P53 expression predict primary refractoriness to first-line pola-R-CHP in patients with diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1887
Abstract: Background: The Pola-R-CHP regimen has emerged as an effective initial treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Nevertheless, a subset of patients demonstrates suboptimal responses. Identifying risk factors for primary refractoriness… read more here.
Keywords: treatment; cd5 positivity; pola; aberrant p53 ... See more keywords
R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1920
Abstract: Introduction: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL), accounts for approximately 30% of newly diagnosed NHL, with approximately 150,000 new cases annually worldwide. The median age at diagnosis is… read more here.
Keywords: treatment; pola; first line; cmop pola ... See more keywords
Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3683
Abstract: Polatuzumab vedotin (Pola), an anti-CD79b monoclonal antibody-drug conjugate, has been approved for first-line treatment of diffuse large B-cell lymphoma (DLBCL) based on results from the POLARIX phase III trial. This study demonstrated that Pola-R-CHP significantly… read more here.
Keywords: cell lymphoma; pola; high risk; cell ... See more keywords
Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3698
Abstract: Dual-expressor DLBCL (DEL), characterized by MYC/BCL2 co-expression (20-30% of cases), demonstrates inferior outcomes with R-CHOP (3-year PFS 30-40%). The POLARIX trial established pola-R-CHP superiority in high-risk DLBCL, with DEL subgroups showing improved 2-year PFS (64.2%… read more here.
Keywords: treatment; dlbcl; pola; risk ... See more keywords
First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7212
Abstract: Objective: To evaluate the efficacy of first-line Pola-R-CHP therapy in patients with high-risk diffuse large B-cell lymphoma (DLBCL) at a single center in China under real-world conditions. Methods: We retrospectively analyzed newly diagnosed CD20-positive DLBCL… read more here.
Keywords: pola chp; line pola; pola; first line ... See more keywords
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14040915
Abstract: Simple Summary Genomic instability (GI) is a transversal phenomenon in oncology, constituting a hallmark of cancer. In gynecological malignancies, the predictive value of GI has been described and is mainly caused by alterations in the… read more here.
Keywords: lurbinectedin plus; trial; plus olaparib; pola ... See more keywords